Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

Conditions:   BRAF NP_004324.2:p.V600M;   BRAF V600E Mutation Present;   Metastatic Thyroid Gland Carcinoma;   Refractory Thyroid Gland Carcinoma;   Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8;   Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8;   Stage IVB Differentiated T hyroid Gland Carcinoma AJCC v8 Interventions:   Drug: Binimetinib;   Drug: Encorafenib;   Biological: Nivolumab Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials